1996

• Sets up a state-of-the-art formulation facility exclusively for manufacture of sterile cephalosporin formulations.
• Receives ISO Certification for Quality Systems.
• Commissions sterile lyophilisation plant.

1997

• Becomes the youngest Indian pharmaceutical company to receive the ISO 9002 Certification.
• Commissions the R&D Centre.
• Launches a range of new products in the sterile category.
• Becomes country's largest producer of oral and sterile cephalosporin.
• Is ranked among the top five producers of cephalosporin APIs.

1998

• Orchid Healthcare, the formulations division becomes operational.

1999

• Receives ISO Certification for Environment Management Systems.

2000

• Acquires a manufacturing plant at Aurangabad.
• Commissions plant for manufacturing nutraceutials.

2002

• Receives the ISO 9001:2000 Certification.
• Sets up a joint venture alliance with a US-based drug discovery research firm Bexel Biotechnology Inc, USA (Bexel).
• Sets up an office in USA.
• Enters into a joint venture with NCPC to set up a manufacturing joint venture in China.

2003

• Acquires domestic formulations company, Mano Pharmaceuticals and enters the chronic therapy segment.
• Sets up an office in Russia.
• Inaugurates new Corporate Office.
• Commissions state-of-the-art Good Laboratory Practices (GLP) compliant pre-clinical facility to support drug discovery.
• Signs an exclusive pact with Apotex to market select sterile antibiotic dosage forms in USA.
• Formulation facilities receive the Therapeutic Goods Administration (TGA) approval. Enables marketing range of cephalosporin bulk drugs (sterile & non-sterile) and non-cephalosporin formulations in Australia and New Zealand.
• European Directorate for the Quality of Medicines (EDQM) & United Kingdom Medicines and Healthcare Regulatory Agency (UK MHRA) successfully inspects API facilities.
• Joint venture with Bexel moves its novel anti-diabetic molecule (BLX-1002) into human clinicals.
• Aurangabad API facility is awarded ISO 14001 and OHSAS 18001 Certification.

2004

• Joint venture with Bexel successfully completes Phase 1 (a) clinical trials on its lead anti-diabetic molecule (BLX-1002).
• Joint venture with Bexel successfully completes Phase 1(b) clinical trials on its lead anti-diabetic molecule (BLX-1002).
• Signs an agreement with Par Pharmaceuticals to market oral cephalosporin formulations in US market.
• Enters into an agreement with Apotex Inc. for an exclusive marketing pact in the Canadian market.
• Joint venture with Bexel successfully completes Phase 2(a) trials on its lead anti-diabetic molecule (BLX-1002). Molecule receives patent clearance from US patent office.
• Enters into a marketing agreement with Par Pharma for non-penicillin and non-cephalosporin (NPNC) products.
• Enters into an agreement with Phoenix for key veterinary injectable product.

2005

• Inks pact with Alpharma to market NPNC dosage forms in US & European markets.
• Enters into a marketing agreement with STADA Pharmaceuticals (USA) for NPNC products.
• Receives GLP Certification. Becomes fifth company in India to be certified for its R&D expertise.
• His Excellency, the then Hon'ble President of India Dr. A.P.J. Abdul Kalam visits Orchid's state-of-the-art formulations manufacturing complex located in the SIPCOT Industrial Estate, Irungattukottai, near Sriperumbudur.
• Medicinal chemistry labs are commissioned in the New Drug Discovery center.
• Enters into an agreement with Mayne Pharma (now Hospira) for marketing injectable antibiotic formulations in selected regulated markets (US, Europe and ANZ).
• Enters into a long-term Master Agreement with Pfizer for certain custom research and manufacturing services (CRAMS).

2006

• Undertakes structural consolidation of global discovery research. Acquires 100% of US discovery entity, Bexel Pharmaceuticals.
• Cephalosporin API and FDF facilities receives UK MHRA approval.
• Signs deal with Biovitrum in drug discovery field.

2007

• UK MHRA approves betalactam API facility located in Aurangabad, near Mumbai.
• Enters into a licensing and distribution alliance with Actavis to market cephalosporin formulations in Europe.
• Forays into the Canadian generic formulations market. Receives Canadian Therapeutic Product Directorate (TPD) approval for two generic formulations.
• Enters into a marketing arrangement with a leading distribution house for oral cephalosporin and non-cephalosporin products.
• Completes the sterile carbapenem API facility in Aurangabad.

2008

• Formulation facilities that manufacture a range of cephalosporin and penicillin injections approved by the Medicines Control Council (MCC), South Africa.
• Completes the sterile carbapenem dosage form facility at Irungattukottai, Chennai.
• Receives the Piperacillin-Tazobactum dossier and ANDS approvals for Australian and Canadian markets.
• Sets up a wholly owned subsidiary in Japan called Orchid Pharma Japan K K (Orchid Japan) to capitalise on the growing Japanese market.
• Undertakes the development of a Novel Anti-coagulant Drug Candidate from Merck and invests in Diakron Pharmaceuticals Inc. (Diakron), a US-based drug discovery and development company, which has an exclusive license agreement with Merck for the compound.
• Enters into a research collaboration and license agreement with Merck to discover, develop and commercialise molecules essential for the treatment of bacterial and fungal infections.

2009

• US FDA approves ANDA for Piperacillin and Tazobactum injection with 6 months exclusivity.
• Orchid inks business transaction agreement with Hospira to transfer the generic injectables formulations dosage form pharmaceutical business for USD 400 million.

2010

• Completes business transfer transaction for sale and transfer of its generic injectable finished dosage forms pharmaceuticals business to Hospira.
• Collaborates with Alvogen to license and market its eight oral non-antibiotic generic formulations.
• Acquires US-based marketing company Karalex Pharma, to strengthen its presence in the front-end US market and to reach its generic products to the US customers directly.
• Orchid redeems FCCBs aggregating to USD 25.69 million.

2011

• Cephalosporin API manufacturing facility at Alathur was successfully re-inspected by USFDA.
• Orchid received milestone payment from Merck on advancement of their research initiative to discover, develop and commercialize molecules essential for the treatment of bacterial and fungal infections.
• Orchid's API Manufacturing facility at Alathur was awarded with OHSAS 18000 : 2007 (Occupational Health and Safety Management System) certification.
• Orchid's API Manufacturing facility at Alathur was re-assessed and was certified with ISO 9001 : 2008 (Quality Management System) and ISO 14001 : 2004 (Environmental Management System).

2012

• Orchid Pharma successfully completed in Europe a Phase I trial of its orally administered PDE4 (phosphodiesterase 4 inhibitor) molecule OCID 2987 positioned for the treatment of inflammatory disorders including COPD (Chronic Obstructive Pulmonary Disease).
• Orchid successfully redeemed the outstanding FCCBs, including yield-to-maturity, aggregating to USD 167.64 million.
• Orchid Pharma enters into agreement to transfer its Penicillin & Penem API business & its API facilities in Aurangabad to Hospira.
• Orchid Pharma exits its Chinese JV with NCPC

2014

• Lenders approve the CDR Package, which included disposal of Non-Penicillin, Non-Cephalosporin (NPNC) Bulk Drug Plant in Aurangabad and the R&D Centre at Sholinganallur.
• The CDR package was implemented in July 2014 and the Lenders took financial control of the Company leaving the Operational matters with the Company Management.

2017

• One of the Operational Creditors moved an application with NCLT, Chennai for admission of the Company into Corporate Insolvency Resolution Process (CIRP) as per IBC 2016 during August 2017.
• NCLT, Chennai admitted the Company in CIRP and the powers of the Board was suspended from August 17, 2017 and the same vested with the IRP /RP appointed by the NCLT Chennai.

2020

• Resolution Plan submitted by Resolution Applicant ~ Dhanuka Laboratories Limited, Delhi, India ~ was approved by the Committee of Creditors and submitted to NCLT Chennai for approval and was duly approved in June 2019, but was stayed by NCLAT, New Delhi in November 2019 and later based on an Appeal by a Financial Creditor the Supreme Court of India upheld the decision of NCLT Chennai in March 2020 and paved way for the implementation of the Resolution Plan.
• The Plan was implemented on March 31, 2020 and the New Board was constituted with the nominations of Board Members from the Resolution Applicant. Orchid Pharma is a Dhanuka Group Company!